Literature DB >> 18802790

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Sebastian Mannweiler1, Peter Amersdorfer, Slave Trajanoski, Jonathan A Terrett, David King, Gabor Mehes.   

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802790     DOI: 10.1007/s12253-008-9104-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

Review 1.  Current practice of Gleason grading of prostate carcinoma.

Authors:  Antonio Lopez-Beltran; Gregor Mikuz; Rafael J Luque; Roberta Mazzucchelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2005-11-23       Impact factor: 4.064

2.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

3.  A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.

Authors:  Ursula Elsässer-Beile; Philipp Wolf; Dorothee Gierschner; Patrick Bühler; Wolfgang Schultze-Seemann; Ulrich Wetterauer
Journal:  Prostate       Date:  2006-09-15       Impact factor: 4.104

4.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Authors:  G L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; P F Schellhammer; R Moriarty
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

5.  Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer.

Authors:  D Bruce Sodee; Adriane E Sodee; George Bakale
Journal:  Semin Nucl Med       Date:  2007-01       Impact factor: 4.446

6.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.

Authors:  J T Pinto; B P Suffoletto; T M Berzin; C H Qiao; S Lin; W P Tong; F May; B Mukherjee; W D Heston
Journal:  Clin Cancer Res       Date:  1996-09       Impact factor: 12.531

7.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

8.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

9.  A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Authors:  P Bühler; P Wolf; D Gierschner; I Schaber; A Katzenwadel; W Schultze-Seemann; U Wetterauer; M Tacke; M Swamy; W W A Schamel; U Elsässer-Beile
Journal:  Cancer Immunol Immunother       Date:  2007-06-20       Impact factor: 6.968

10.  Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer.

Authors:  Zhao Zhigang; Shen Wenlv
Journal:  World J Surg Oncol       Date:  2004-05-10       Impact factor: 2.754

View more
  110 in total

1.  NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.

Authors:  Hongying Huang; Sergei R Guma; Jonathan Melamed; Ming Zhou; Peng Lee; Fang-Ming Deng
Journal:  Am J Clin Exp Urol       Date:  2018-10-20

2.  Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Authors:  Steven M Santana; He Liu; Neil H Bander; Jason P Gleghorn; Brian J Kirby
Journal:  Biomed Microdevices       Date:  2012-04       Impact factor: 2.838

Review 3.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Writing PET into existence.

Authors:  A Chiti; M Kirienko; E Incerti; M Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

Review 5.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

6.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

7.  Editorial Comment: Advances in MRI and PET of the prostate: concurrence or complementarity?

Authors:  Raphaële Renard-Penna; Mathieu Gauthé; Jean-Noël Talbot
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

8.  Histological heterogeneity between primary and metastatic cancer in a pathologic confirmed case of isolated optic disc metastasis of prostate adenocarcinoma.

Authors:  Hyun Seung Yang; Hye Rin Jeong; Chul Woo Kim; Young Hee Yoon; June-Gone Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-28       Impact factor: 3.117

9.  Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Authors:  Mark A Castanares; Ben T Copeland; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Martin G Pomper; Shawn E Lupold; Catherine A Foss
Journal:  Prostate       Date:  2015-10-26       Impact factor: 4.104

10.  Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Authors:  Scott T Tagawa; Matthew I Milowsky; Michael Morris; Shankar Vallabhajosula; Paul Christos; Naveed H Akhtar; Joseph Osborne; Stanley J Goldsmith; Steve Larson; Neeta Pandit Taskar; Howard I Scher; Neil H Bander; David M Nanus
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.